Pfizer back in obesity game via $4.9B Metsera deal

After years of falling behind in the obesity race, Pfizer is back in the game with its acquisition of obesity play Metsera, giving the pharma multiple oral and injectable clinical programs that have best-in-class potential.

The move comes just five months after it appeared that Pfizer Inc. (NYSE:PFE) was throwing in the towel in obesity. In April, the pharma said it discontinued development of its oral small molecule GLP-1R agonist danuglipron after observing a liver injury signal in a Phase III trial. That was the second time Pfizer had abandoned a small molecule GLP-1R agonist for liver toxicity issues, as it had encountered the same problem with lotiglipron in 2023...